瑞典589 722人中新冠疫苗对新冠感染后状态的有效性:基于人群的队列研究
该研究基于瑞典SCIFI-PEARL登记队列,纳入2020年12月27日至2022年2月9日首次登记新冠感染的589 722名成年人,随访至2022年11月30日。接种任意剂次疫苗者发生新冠感染后状态(PCC)的风险低于未接种者(调整HR 0.42,95%CI 0.38至0.46),疫苗有效性为58%;随接种剂次增加,有效性分别为21%、59%和73%。
要点
- 接种任意剂次新冠疫苗者PCC诊断率0.4%(1201/299 692),未接种者1.4%(4118/290 030)。
- 调整后HR 0.42(95%CI 0.38至0.46),疫苗有效性58%。
- 一剂、两剂、三剂及以上疫苗有效性分别为21%、59%、73%。
核心结论
- 研究结果提示,感染前接种新冠疫苗与降低PCC诊断风险存在强关联。
- 研究结果强调基础接种新冠疫苗对减轻PCC人群负担的重要性。
研究设计与样本
- 基于人群的队列研究,数据来自瑞典SCIFI-PEARL登记链接项目。
- 纳入瑞典两个最大区域2020年12月27日至2022年2月9日首次登记新冠感染的589 722名成年人(≥18岁)。
- 随访从首次感染至死亡、移民、接种疫苗、再感染、PCC诊断(ICD-10诊断码U09.9)或随访结束(2022年11月30日),以先发生者为准。
- 感染前至少接种一剂新冠疫苗者视为接种组;采用Cox回归调整年龄、性别、合并症、2019年医疗接触次数、社会经济因素及感染时优势病毒变异株。
主要发现
- 接种组299 692人中1201人(0.4%)随访期间诊断PCC,未接种组290 030人中4118人(1.4%)诊断PCC。
- 感染前接种任意剂次疫苗与PCC风险降低相关(调整HR 0.42,95%CI 0.38至0.46),疫苗有效性58%。
- 接种组中21 111人仅接种一剂,205 650人接种两剂,72 931人接种三剂及以上。
- 一剂、两剂、三剂及以上疫苗对PCC的有效性分别为21%、59%、73%。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effectiveness of primary covid-19 vaccination (first two doses and first booster dose within the recommended schedule) against post-covid-19 condition (PCC). DESIGN: Population based cohort study. SETTING: Swedish Covid-19 Investigation for Future Insights-a Population Epidemiology Approach using Register Linkage (SCIFI-PEARL) project, a register based cohort study in Sweden. PARTICIPANTS: All adults (≥18 years) with covid-19 first registered between 27 December 2020 and 9 February 2022 (n=589 722) in the two largest regions of Sweden. Individuals were followed from a first infection until death, emigration, vaccination, reinfection, a PCC diagnosis (ICD-10 diagnosis code U09.9), or end of follow-up (30 November 2022), whichever came first. Individuals who had received at least one dose of a covid-19 vaccine before infection were considered vaccinated. MAIN OUTCOME MEASURE: The primary outcome was a clinical diagnosis of PCC. Vaccine effectiveness against PCC was estimated using Cox regressions adjusted for age, sex, comorbidities (diabetes and cardiovascular, respiratory, and psychiatric disease), number of healthcare contacts during 2019, socioeconomic factors, and dominant virus variant at time of infection. RESULTS: Of 299 692 vaccinated individuals with covid-19, 1201 (0.4%) had a diagnosis of PCC during follow-up, compared with 4118 (1.4%) of 290 030 unvaccinated individuals. Covid-19 vaccination with any number of doses before infection was associated with a reduced risk of PCC (adjusted hazard ratio 0.42, 95% confidence interval 0.38 to 0.46), with a vaccine effectiveness of 58%. Of the vaccinated individuals, 21 111 received one dose only, 205 650 received two doses, and 72 931 received three or more doses. Vaccine effectiveness against PCC for one dose, two doses, and three or more doses was 21%, 59%, and 73%, respectively. CONCLUSIONS: The results of this study suggest a strong association between covid-19 vaccination before infection and reduced risk of receiving a diagnosis of PCC. The findings highlight the importance of primary vaccination against covid-19 to reduce the population burden of PCC.
引用
- Lundberg-Morris L, Leach S, Xu Y, et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ. 2023. PMID: 37993131. doi:10.1136/bmj-2023-076990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。